Life Sciences Archive » April, 2013

Life Sciences - April, 2013

300 articles

• Teva, Orchid Settle Patent Dispute Over Azilect
• Teva Loses Amgen Spying Suit Over Blood Drug Secrets
• Compounding Bill May Hand FDA New Power Over Health Care
• Plan B Approved For Ages 15 And Up Without Prescription
• No Shrinkage Of $459M Fine For Male Enhancement Maker
• Bayer Workers Want Clock Stopped In $100M Sex Bias Case
• Humira Was A Factor In Widespread Infection, Doctor Testifies
• German Court Halts Sales of Boston Scientific Stents
• SportPharm Seeks Indemnity In Ex-USC Player's Pain Med Suit
• Sealing The Deal: O'Melveny Nails Historic Buy For China's BGI
• Forest Labs Says 3rd $100M Sex Bias Complaint Still Flawed
• EU Court Blocks Regulator From Releasing Drug Trial Data
• EU's New Package Of Consumer Product Safety Rules
• Eli Lilly Says It Warned Doctors Of Cymbalta 'Brain Zaps'
• Novartis Dismissed Drugs' Link To Bone Death, Doc Testifies
• After Win, FDA May Backtrack On More Device Approvals
• Merck Wins First Femur-Related Fosamax Suit
• Merck Escapes Suits Over Prescription Copay Coupons
• Qiagen Buys Genetic Data Processor In $105M Cash Deal
• FDA Rejects Pair Of Gilead HIV Drugs
• P&G Asks 11th Circ. To Bar Experts In Fixodent Case
• GSK Changes Potiga Label In Response To Eye, Skin Issues
• Schumer Pushes For Further Hydrocodone Restrictions
• Husch Blackwell Adds Product Liability Pro From Jenner
• Bard Dodges Bid To Remand Vascular Filter Defect Suit
• Sullivan & Cromwell Guides Bayer's $1.1B Conceptus Buy
• Auxilium Inks $657M Deal For Erectile Dysfunction Drug Co.
• Pharma IP Rights In China: Avoiding The Antitrust Pitfalls
• Second NJ Trial Underway In Novartis Bone Drug Litigation
• Cancer Treatment Device Maker Beats Antitrust Claims
• Patient Wins $6.5M Award In 1st Actos Bladder Cancer Trial
• CareFusion To Pay $41M To End Marketing Probe
• Advance Realty Buys Former Sanofi Research Campus In NJ
• K-V Lenders Slam Creditors' Objections Over Plan Statement
• Smith & Nephew Hip Implant Suit Booted
• Fed. Circ. Allows For Some Ambiguity In Patent Claims
• Novartis Faces Another DOJ Suit Over Alleged Kickbacks
• White House Names FTC's Shelanski To Lead Oversight Body
• AstraZeneca Didn't Deserve Seroquel Extension, DC Circ. Says
• Theravance To Split To Create Firm Focused On GSK Tie-Up
• Greenberg Fends Off DQ Bid In Drug-Discount Antitrust Suit
• FDA Flubbed Approval Of Generic Cattle Med, Judge Says
• Bill Giving FDA New Power Over Compounders Unveiled
• ITC Launches Probe Of Imported Sleep Aid Devices
• Wright Accuses Arthrex Of Medical Device Trademark Ripoff
• Sequester Will Hinder Drug, Device Reviews, FDA Head Says
• Purdue, Actavis Settle OxyContin Patent Battle
• Branded, Generic Cos.' Reglan Win Stands In Appeals Court
• Foley Adds Former K&L Health Care Pro To Boston Team
• Hemispherx Misled Investors Over Anti-Fatigue Drug, Suit Says
• Abbott's Humira Letter Needed FDA's Green Light, Jury Told
• Shire Ends Patent War With Actavis, Watson Over ADHD Drug
• NuVasive Hit With Patent Suit Over Bone Screw Device
• AstraZeneca Hit With US Subpoena Over UK Plant
• Obagi Chase Ends As Investors Approve $414M Valeant Bid
• Edwards Says Heart Valve IP Still Infringed After $74M Verdict
• Belgian Drug Co. Shores Up US Biz With Okla. Distributor Buy
• Deals Rumor Mill: Verizon, Telefonica, 3i
• It's My Expert, And I'll Call Her If I Want To
• FDA Surveillance Could Actually Help Device Makers In Court
• Baxter Units Face IP Suit Over Actifuse Bone Graft Product
• 3SBio Exec, PE Firm Put Up $380M To Sweeten Go-Private Bid
• Senate Confirms Burwell As New OMB Head
• Novartis Reveals Probe Of Plant Quality Issues
• Humira Caused Serious Fungal Infection, Jury Hears
• Pharma Cos. Get Cert. In MDL Over Generic Prograf Delays
• NY Turns To Insurers To Battle Meningitis Outbreak
• FDA Unveils Tool To Detect Counterfeit Products
• Omnicare Faces Probe Over Possible FCA Offenses, Kickbacks
• IP Firm Hit With $4M Malpractice Suit Over Patent Case
• GSK Looks To Unload Lucozade, Ribena Energy Drink Brands
• FDA Head Touts Deeper Patient Input In Drugmaking Process
• Pfizer Escapes Shareholder Suit Over Wyeth Alzheimer's Drug
• Law Firms Take A Liking To Social Media Practice Groups
• FDA Releases Draft Guidance On Improved Drug Labels
• DOJ Sues Novartis Over Alleged Myfortic Kickback Scheme
• Stryker's New Claims Over XL Settlement Meet Resistance
• Ind. Compounder Recalls Drugs Over Sterility Concerns
• FTC Clears Nordic Capital's $767M Sale Of Wheelchair Co.
• FDA's OxyContin Ruling May Spur New Battles Over Generics
• Allergan, Duke Block Lash-Growth Generics
• Caronia And Harkonen — Lessons For The Gov't
• Promega Denied Do-Over On $52M Gene-Testing Patent Verdict
• Merck's NuvaRing Win Puts Pressure On MDL Plaintiffs
• FDA Cracking Down On Compounders At Historic Pace
• Justices Let Hearing-Aid Makers' $31M Patent Judgment Stand
• Stryker Urges Rejection Of Zimmer Bid For New Patent Trial
• Walgreen Hawked Bogus Joint Health Supplements, Suit Says
• Elan Rejects Royalty's New Takeover Bid After Stock Buyback
• OIG's Alert Has Broad Implications With A Hint Of Warning
• An Update On Daubert And Class Certification
• Pfizer Sues Inventia Over Generic Bladder-Control Drug
• Sanofi Can't Duck Amphastar's FCA Suit Over Lovenox
• Shire Settles Patent Row With Sandoz Over Generic Intuniv
• High-Risk Implants Need Toughest FDA Review, Group Says
• Grand Jury To Probe Compounder Over Meningitis Outbreak
• FDA Proposes OK Of Usage Symbols On Medical Devices
• Famed Tort Litigator Stanley Chesley Retires Amid Scandal
• Red Cross Says J&J's Anti-Bleeding Patches Infringe Patents
• Ingredient Maker Escapes Liability In Drug Recall Suit
• UK Antitrust Watchdog Hits GSK With Pay-For-Delay Claims
• GNC Hit With False Ad Claims Over Triflex Joint Product
• A Guide To Effective Environmental Due Diligence
• A New Weapon In Generic Drug Companies' Arsenal
• Africa — Open For Business
• Life Tech Investor Sues To Block $13.6B Buyout
• Generic MS Drug Development Was Protected, Sandoz Says
• Diabetes Drugs Have High Rate Of Cancer Links: Report
• J&J Win Highlights FDA's Impact On Hip Implant Cases
• FDA To Survey Docs, Nurses On Drug Advertising
• BakerHostetler Lures Ex-Fulbright Atty To Head FDA Group
• UK Appeals Court Sends Singulair Arguments To EU Court
• How Elan's $1B Buyback Shakes Up Looming Hostile Bid
• Insurers Win Bid To Return Avandia, Paxil Suits To Pa. Court
• Elan Buys Back Shares From J&J As $7B Bid Hangs Overhead
• Univ. Of Ala. Study Caused Infant Deaths, Suit Claims
• Kiobel Ruling Curbs Potential ATS Liability — For Now
• 3 Ways To Leverage Internet Access During Trial
• Depomed Hits Endo With Patent Suit Over Opana ER
• Galderma Must Pay Oracea Fees To NYU During Appeal
• Takeaways From 2nd-Ever Bermuda Form Insurance Case
• 5th Circ. Quashes Generic Reglan Failure-To-Warn Suit
• Roche Urges Fed. Circ. To Revive Boniva Patents
• Fla. Senate Panel Clears Bill To Strengthen State FCA
• Cooley Nabs Ex-Epstein Becker Health Practice Head
• High Court Urged To Revive Pfizer, GSK Price-Fixing Suit
• FDA Again Rejects Allergan Migraine Drug Levadex
• Volcano Hits St. Jude With New Suit In Guide Wire IP Feud
• Pharma Cos. Say Whistleblower's FCA Case Recycles Old Suits
• Get Your Facts Fast — FOIA Requests May Be Expedited
• Dems Propose Bill To Cut $141B In Medicare Drug Costs
• J&J, Dozen Other Cos. Sued Over Fluid Delivery Patent
• Jury Sides With DePuy At 2nd Hip Implant Trial
• FDA Staff Has Concerns Over Endo Testosterone Replacement
• Amgen To Pay $25M To Escape Anemia Drug Kickback Suit
• Bayer Asks 3rd Circ. To Decertify Class In Vitamin Ads Row
• FDA Blocks OxyContin Generics, Citing Abuse Risks
• Nobel Biocare To Pay Up To $1.3M To Settle Dental Implant Suit
• GSK Backed By Fed. Circ. In Leukemia Drug Patent Suit
• Plan B Should Be Over-The-Counter, Medical Groups Say
• Thoughts On Oral Arguments In Gene Patent Case
• FDA Head Admits Missteps In Run-Up To Meningitis Outbreak
• Bayer's Yaz Patent Claims Are Invalid, Fed. Circ. Says
• K-V Creditors Say Alternative Plan Is In The Works
• Alzheimer's Institute Seeks New Trial In UPenn Patent Row
• CORRECTED: Bayer Wants Rival's Flea-Killer Ads Exterminated
• Novartis Didn't Properly Test Hypertension Drugs, Suit Says
• Actos Plaintiff Deserves $5.3M For Bladder Cancer, Jury Told
• Takeda Put Actos Profits Before Patient Safety, Jury Told
• 11th Circ. Revives FTC False Ad Claim Over Supplements
• FDA To Help Drugmakers Take To Twitter, Official Says
• Justices Cast Skeptical Eye On Human Gene Patents
• DePuy Should Pay $5M For Implant 'Catastrophe,' Jury Hears
• Mexico Clears $12B Nestle-Pfizer Deal After Divestiture
• White & Case Reps Harvest In Infusion Therapy Co. Buy
• Hedge Funds Sue Pharma Co. Over $20M Note Default
• Compounders Need FDA Oversight, Markey Says
• Attorneys Reap $17.2M In Becton Antitrust Dispute
• Wachtell Guides Thermo Fisher's $13.6B Life Tech Takeover
• High Court Won't Mull Double Avandia Damages For Insurers
• How Bowman V. Monsanto May Wreak Havoc On Biotechnology
• DC Circ. Won't Kill FTC Bid For Boehringer Deal Docs
• Groups Sweat Scope Of High Court Gene Patent Ruling
• FDA Lists Poor Conditions At Compounding Pharmacies
• EU Antitrust Chief Expects First Libor Case In 2013
• FDA's Approval Of Generic Bayer Bovine Drug Suspended
• Safety Controls Eyed As New Way To Block Generic Drugs
• Merck's Fosamax Caused Broken Femur, NJ Jury Hears
• FDA To Reassess Avandia Risk After Revisited Study
• Meningitis Plaintiffs' Litigation Team Named In NECC Case
• Wal-Mart, Rite Aid Face Suit Over Glucosamine Promises
• Shire Sues Neos To Block Adderall XR Competitor
• Steptoe Lures EU Regulatory Team In Brussels
• $967B Proposed HHS Budget Receives Little GOP Pushback
• Dorsey Lures IP, White Collar Ace To Minneapolis Office
• Elan Investors OK $1B Buyback As Royalty Pharma Looms
• Manufacturers, Be Sure To Read These Tea Leaves
• Biolitec Held In Contempt Over Merger In AngioDynamics Row
• Chinese Co. Wants $153M Award Vacated In Vitamin C MDL
• Ex-FTC Head Predicts Partial Win On Pay-For-Delay
• Defunct Pfizer Unit Ends Appeal Of $8.7M Asbestos Verdict
• Stryker Recall Gets FDA's Most Serious Classification
• Schedule Killed Pfizer IP Suit, AntiCancer Tells Fed. Circ.
• Most Hospitals Use Compounded Sterile Drugs, HHS Says
• AstraZeneca Settles Generic Seroquel XR Row With Lupin
• Bayer Vitamin Claims Not Demonstrably False, Judge Finds
• DePuy Hip Implant Patient Likely Hypersensitive, Jury Hears
• Integra Recalls Collagen Products After Manufacturing Woes
• Merck Can't Boot Witnesses From Bellwether Fosamax Trial
• Bayer Sues FDA Over Approval Of Generic Cattle Antibiotic
• Post-Merck Debate Over Research Exemption For Infringement
• Sound The Alarm: Uninjured Plaintiffs Now Have Standing
• Obama Proposes Funding Boost To Drug, Tobacco Oversight
• Pfizer Breast Cancer Drug Gets FDA's 'Breakthrough' Status
• Sanofi Can't Revive Antitrust Counterclaim In Vaccine Case
• FDA Sets Consumer Test Policies As It Mulls Widening OTCs
• Mylan Blasts Apotex Challenge To Generic Benicar Exclusivity
• Actavis Settles With Medicis Over Skin Drug Generic Plans
• Bingham McCutchen Reels In DLA Piper IP Pros For LA Office
• Deals Rumor Mill: Marlin Equity, Life Tech, Dell
• Va. Takes The Lead In Biosimilar Substitution Law
• 4 Industries Facing New Heat From The False Claims Act
• Black Eye Aside, KPMG May Sidestep Legal Melee
• Merck Ignored Fosamax Femur Injury Warnings, Jury Told
• Philips Pays $5M To Settle SEC Suit Over Polish Bribes
• House Dems Want More Info On Animal Antibiotics Use
• Texas Court Won't Revive $10M Award Against Fen-Phen Atty
• Plan B Ruling Curbs FDA's Power To Restrict Drug Access
• Investors In $132M Vitacost IPO Ask 11th Circ. To Revive Suit
• FDA Warns Pfizer Italian Unit Over Contamination
• Impax Misled Investors About Manufacturing Issues, Suit Says
• Beware Pharmacy Record-Keeping Violations
• Preemption Of Research Has No Place In Gene Patent Case
• KPMG Resigns As Herbalife Auditor Amid Trading Scandal
• Nutrisystem Defeats Class Cert. Bid In Call Recording Suit
• High Court Case Could Strike Down Human Gene Patents
• Human Egg Donors' Price-Fixing Suit Survives Dismissal Bid
• Hospitals Win Delay In Drug Discount Program Deadline
• NeurogesX Can't Shake Shareholder Suit Over Exec's Exit
• Sister Of Jailed Insider Trader Nguyen Settles SEC Suit
• Stryker Hip Implant Litigation In NJ Heads To Mediation
• NJ Judge Tailors Evidence In Novartis Bone Drug Mass Tort
• Fed. Circ. Calls Foul On Cephalon's Provigil Patent
• J&J Vaginal Mesh Plaintiff Can't Remove Suit From MDL
• Scottsdale Owes Wrinkle Treatment Injury Defense, Coapt Says
• FDA Isn't Cracking Down On Social Media Ads, Report Says
• Illumina Fires Back At Suit Over Rejected $9B Roche Bid
• Merz Pharma Drops Out Of Bidding War For Obagi Medical
• Jones Day Adds Food And Drug Pro From Hunton & Williams
• Union Fund Hits Reckitt With Suboxone Antitrust Suit
• Deals Rumor Mill: Google, Billabong, Icahn
• Warner Chilcott Sued Over Loestrin Pay-For-Delay Deals
• Allergan Botox Case Should Be Killed, Del. High Court Says
• Merck Loses Injunction Bid In Generic Diabetes Drug Suit
• Greenberg Blasts DQ Bid In Drug-Discount Antitrust Suit
• Lax Ga. False Claims Law May Threaten Medicaid Incentives
• Cordis, Wyeth Urge Fed. Circ. To Revive Stent Patents
• FDA's Light Touch With Medical Apps May Let Industry Bloom
• Promega DNA Products Infringe Caltech Patent, Judge Finds
• CORRECTED Saul Ewing Adds 2 Edwards Wildman IP Attnys In Boston
• Mako's Trade Secrets Win Sidelines Rival's Sales Staffer
• Sun Pharma Agrees Not To Sell Generics Of Sleep Aid Lunesta
• Bausch & Lomb Fires Back At Eye Doctor's Trademark Claims
• FDA Must Make Plan B Available To All Women, Judge Rules
• Security Co. Blasts Lilly Insurer's $80M Drug Theft Suit
• Mintz Hires Product Liability Pair In San Francisco
• Let's Fix The Patent-Specific Preliminary Injunction Test
• Inside The FTC's Take On Generic Access To Branded Drugs
• St. Jude Defibrillator Wires Had Fatal Defects, Suits Say
• AbbVie, Teva Accused Of Pay-For-Delay On Generic Niaspan
• Pharmacists Urge Medicare Part D Plans To Follow CMS' Lead
• Supplement Trade Group Floats Voluntary Caffeine Rules
• Fed. Circ. Wipes Out $600M Patent Judgment Against J&J
• FDA Biosimilar Meetings Offer Chance To Skip Clinical Trials
• Ferring Loses Bid To Halt Ads For Watson Fertility Drug
• Chicago Law Firm Botched Vitacost's $132M IPO, Suit Says
• ACLU Joins Prescription Drug Privacy Row With DEA
• Ex-FDA Official Says DePuy Followed Hip Implant Watch Rules
• 'All Natural' ED Products Contain Hidden Risks, FDA Warns
• Dickstein Shapiro Adds Ex-Elan IP Head In Silicon Valley
• Purdue Targets Dr. Reddy's In Growing Sleep-Aid Patent Blitz
• Celgene's $5.5M Patent Buy Ends Cancer-Therapy IP Row
• A Narrow Exception To The Mensing Preemption Defense
• No Defense Reimbursement For Insurers In Wash.
• ViroPharma Didn't Defame Fired Janitors, Appeals Court Says
• Mobile Medical Apps Invite New Breed Of Product Suits
• Justices Seek Word From Amphastar In Drug Safe Harbor Case
• 1st Circ. Rules Against Pfizer In 3 Neurontin RICO Suits
• Novartis Sues Noven To Block Generic Dementia Patch
• Valeant Bids $418M To Keep Top Spot In Obagi Bidding War
• Parker Waichman Backs Bayer Over NJ Mirena Consolidation
• Troutman Sanders Beats Conflict Of Interest Claims
• Cephalon's Provigil Patent Is Enforceable, Fed. Circ. Told
• Bayer Beats Failure-To-Warn Action In Trasylol MDL
• How Lawyers Benefit From Early Neutral Evaluation
• Precision For Medicine Pulls In $150M In PE Funding
• Shire Faces Consumer Antitrust Claims Over Adderall
• Mylan Settles With Sunovion Over Lunesta Generic Plans
• DePuy Hip Developer Says He Wouldn't Use Implant
• Suit Pins Pancreatic Cancer Deaths On Merck Diabetes Drug
• Obama Launches $100M Brain Research Initiative
• Chinese Co. Northeast Settles Vitamin C Antitrust Claims
• AmerisourceBergen Brings In $308M For Pharma-Packing Unit
• Merz Tops Valeant With $383M Bid For Obagi
• AstraZeneca's Kid Asthma Drug Patent Invalid, Judge Says
• The Next Big Thing For Medical Device Clinical Studies
• Cephalon Beats Challenge To Narcolepsy Drug Patent
• Immunomedics Agrees To $18M Settlement With Broker-Dealer
• Virginia Law Raises Red Flags For Biosimilar Industry
• Pfizer Dodges Suit Over Retirement Fund Stock Plummet
• Generic Co. Lobs Antitrust Suit To Access Brand-Name Meds
• Chamber Asks High Court To Hear Fight Over FCA Changes
• J&J Must Face Tylenol Liver Damage MDL In Pa.
• Patterson Atty Gained Secrets Through Ruse, Doc Says
• Fla. Bill Axing Sales Tax On Industrial Gear Clears Panel
• Martek Dodges Antitrust Suit Over Baby Formula Additives
• India's High Court Blocks Novartis Patent, Boosting Generics
• US To Argue In High Court Challenge Of Myriad Gene Patents
• Breaking Down The Bartlett Oral Argument
• The Supreme Court Is Paying Attention To Patent Law Again